309 studies found for:    Open Studies | bone marrow transplantation
Show Display Options
Rank Status Study
21 Recruiting Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Radiation: radiation therapy;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
22 Recruiting Treosulfan and Fludarabine Phosphate With or Without Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation;   Drug: Treosulfan
23 Recruiting Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
Condition: Non-Malignant
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
24 Recruiting NK Cells to Prevent Disease Relapse for Patients High Risk Myeloid Malignancies
Conditions: Leukemia;   Myeloproliferative Diseases
Interventions: Drug: Melphalan;   Drug: Fludarabine;   Procedure: Expanded NK Cell Infusion;   Procedure: Bone Marrow Transplant;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Radiation: Total Body Irradiation (TBI)
25 Recruiting Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
Conditions: Severe Aplastic Anemia;   Bone Marrow Failure Syndromes
Interventions: Procedure: Bone marrow transplant;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Mesna;   Drug: Tacrolimus;   Drug: Mycophenolic acid mofetil
26 Recruiting Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Conditions: Dyskeratosis Congenita;   Hoyeraal Hreidarsson Syndrome;   Revesz Syndrome;   Aplastic Anemia
Interventions: Biological: alemtuzumab;   Drug: Fludarabine;   Drug: Cyclosporins;   Drug: Mycophenolate mofetil
27 Unknown  Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children
Condition: Benign Disease
28 Recruiting Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Melphalan;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
29 Recruiting Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Condition: Leukemia
Interventions: Biological: recombinant interferon alfa;   Drug: cytarabine;   Drug: hydroxyurea;   Drug: imatinib mesylate;   Procedure: allogeneic bone marrow transplantation;   Procedure: autologous bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
30 Recruiting Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis
Conditions: Systemic Scleroderma;   Severe Systemic Sclerosis
Interventions: Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
31 Recruiting Donor Human Milk in Young Children Receiving Bone Marrow Transplantation
Condition: Bone Marrow Transplant - Autologous or Allogeneic
Intervention: Biological: Breastmilk
32 Recruiting Double Cord Versus Haploidentical (BMT CTN 1101)
Conditions: Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Burkitt's Lymphoma;   Follicular Lymphoma;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Biological: Haploidentical Bone Marrow Transplant;   Biological: Double Umbilical Cord Blood Transplant
33 Recruiting Eltrombopag in Cord Blood or Haploidentical Bone Marrow Transplantation
Condition: Blood And Marrow Transplantation
Intervention: Drug: Eltrombopag
34 Recruiting Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant
Condition: Bone Marrow Transplant
35 Recruiting Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Conditions: Multiple Myeloma;   Bone Marrow Failure Syndromes;   Hemoglobinopathies;   AML;   ALL;   Myeloid Leukemia, Chronic;   NHL;   HL;   MDS;   Amyloidosis;   Myelofibrosis
Interventions: Drug: Tacrolimus;   Drug: Anti-thymocyte globulin;   Procedure: Kidney transplant;   Drug: Bone marrow transplant from a related donor;   Radiation: Total body irradiation 400 centigray (200 cGy X 2)
36 Recruiting Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia
Interventions: Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: CXCR4 Antagonist;   Procedure: Hematopoietic Stem Cell Transplantation
37 Recruiting Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Bone Marrow Transplantation Patients
Condition: Neoplasms
Intervention: Other: buccal swabs and obtaining peripheral blood
38 Recruiting Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
Conditions: Acute Leukemia;   Myelodysplasia
Interventions: Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate;   Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft;   Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Methotrexate
39 Recruiting Bone Marrow Transplantation and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
Condition: Kidney Transplantation
Interventions: Biological: Antithymocyte globulin (ATG);   Drug: Fludarabine;   Drug: Low dose Pre-transplant cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Methylprednisolone;   Biological: Bone Marrow;   Drug: MESNA;   Drug: Mycophenolate mofetil (MMF);   Drug: Prednisone;   Drug: Filgrastim;   Drug: High dose post-transplant cyclophosphamide
40 Recruiting Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
Conditions: Severe Combined Immunodeficiency (SCID);   Immunodeficiency With Predominant T-cell Defect, Unspecified;   Severe Chronic Neutropenia;   Chronic Granulomatous Disease (CGD);   Hyper IgE Syndromes;   Hyper IgM Deficiencies;   Wiskott-Aldrich Syndrome;   Mendelian Susceptibility to Mycobacterial Disease;   Common Variable Immune Deficiency (CVID)
Intervention: Biological: CD3/CD19 negative allogeneic hematopoietic stem cells

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years